Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Seasonal Trends in Biotech: Preparing for the Future with EvoLV

Sep 16, 2025

Understanding Seasonal Trends in Biotech

The biotech industry, known for its rapid innovation and groundbreaking advancements, is heavily influenced by seasonal trends that can dictate the trajectory of research, development, and market dynamics. As we look towards the future, understanding these trends becomes essential for companies aiming to stay ahead. EvoLV, a leader in the biotech sector, is at the forefront of leveraging these trends to drive progress.

Seasonal trends in biotech are often shaped by factors such as funding cycles, regulatory changes, and technological advancements. These elements can create opportunities for growth or pose challenges that require strategic navigation. EvoLV’s proactive approach includes continuous monitoring and adapting to these shifts, ensuring they remain competitive and innovative.

biotech innovation

The Impact of Funding Cycles

One of the most significant seasonal influences in biotech is the annual funding cycle. Many biotech companies rely on grants and investments that are often distributed at specific times of the year. EvoLV has developed strategies to align their projects with these cycles, maximizing their funding potential and ensuring steady progress throughout the year.

To adapt to these cycles, EvoLV conducts thorough market analyses and maintains robust relationships with investors. This enables them to anticipate changes and secure the necessary resources to advance their projects effectively.

Regulatory Changes and Their Influence

Regulatory changes are another critical factor influencing seasonal trends in biotech. Governments and regulatory bodies frequently update policies that can impact product development timelines and market entry strategies. EvoLV closely monitors these changes to ensure compliance and optimize their strategic planning.

regulatory compliance

By staying informed and proactive, EvoLV can quickly adapt to new regulations. This agility allows them to minimize disruptions and capitalize on emerging opportunities, maintaining a competitive edge in a rapidly evolving industry.

The Role of Technological Advancements

Technological advancements are at the heart of biotech innovation. Seasonal trends often reflect the introduction of new technologies or methodologies that transform research and development processes. EvoLV is committed to integrating cutting-edge technologies into their work to enhance efficiency and outcomes.

The company's investment in technology not only supports current projects but also positions them for future breakthroughs. By staying at the forefront of technological trends, EvoLV ensures they can deliver innovative solutions that meet market demands.

biotech technology

Preparing for Future Trends

EvoLV’s approach to seasonal trends extends beyond current adaptations; they actively prepare for future shifts by fostering a culture of continuous learning and innovation. This involves investing in employee development, supporting collaborative research initiatives, and exploring emerging markets.

Looking ahead, EvoLV aims to expand their influence by focusing on sustainability and ethical practices. By aligning with global efforts to address environmental concerns and social responsibilities, they set a precedent for responsible growth in the biotech sector.

In conclusion, understanding and adapting to seasonal trends is crucial for success in the biotech industry. EvoLV's strategic focus on funding cycles, regulatory changes, and technological advancements positions them as a leader prepared for the future. As they continue to innovate and evolve, EvoLV exemplifies how businesses can thrive amidst change by embracing it as an opportunity for growth.